Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium

WILMINGTON, Del., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced the publication of three abstracts regarding its SMARCA Degrader Programs at the 36^th EORTC-NCI-AACR Symposium taking place in Barcelona, Spain October 23-25, 2024. The abstracts can be found at Conference (eortc.org).